MA38827A1 - Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives - Google Patents

Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives

Info

Publication number
MA38827A1
MA38827A1 MA38827A MA38827A MA38827A1 MA 38827 A1 MA38827 A1 MA 38827A1 MA 38827 A MA38827 A MA 38827A MA 38827 A MA38827 A MA 38827A MA 38827 A1 MA38827 A1 MA 38827A1
Authority
MA
Morocco
Prior art keywords
inhibitor
treatment
combination
hyperproliferative diseases
erk
Prior art date
Application number
MA38827A
Other languages
English (en)
Inventor
Marcia Belvin
John Moffat
Mark Merchant
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38827A1 publication Critical patent/MA38827A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des combinaisons comprenant un inhibiteur de mek (comme gdc-0973 ou gdc-0623) ou d'un sel pharmaceutiquement acceptable de celui-ci et d'un inhibiteur d'erk (comme gdc-0994). Les combinaisons sont particulièrement utiles pour traiter des troubles hyperprolifératifs, tels que le cancer.
MA38827A 2013-09-05 2014-09-04 Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives MA38827A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874206P 2013-09-05 2013-09-05
PCT/EP2014/068776 WO2015032840A1 (fr) 2013-09-05 2014-09-04 Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives

Publications (1)

Publication Number Publication Date
MA38827A1 true MA38827A1 (fr) 2017-10-31

Family

ID=51492945

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38827A MA38827A1 (fr) 2013-09-05 2014-09-04 Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives

Country Status (21)

Country Link
US (1) US9532987B2 (fr)
EP (1) EP3041471A1 (fr)
JP (2) JP2016531139A (fr)
KR (1) KR20160048807A (fr)
CN (1) CN105517548B (fr)
AR (1) AR097556A1 (fr)
AU (1) AU2014317119B2 (fr)
CA (1) CA2916619A1 (fr)
CL (1) CL2016000042A1 (fr)
EA (1) EA034872B1 (fr)
HK (1) HK1218072A1 (fr)
IL (1) IL243251B (fr)
MA (1) MA38827A1 (fr)
MX (1) MX370417B (fr)
PE (1) PE20160529A1 (fr)
PH (1) PH12016500270A1 (fr)
SG (1) SG11201600989VA (fr)
TW (1) TW201605477A (fr)
UA (1) UA120423C2 (fr)
WO (1) WO2015032840A1 (fr)
ZA (1) ZA201600091B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180591T1 (hr) * 2012-03-01 2018-05-18 Array Biopharma, Inc. Inhibitori kinaze serina ili treonina
EP3077401B1 (fr) 2013-12-06 2018-04-18 Genentech, Inc. Inhibiteurs de sérine/thréonine kinase
MX375902B (es) * 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
WO2016162325A1 (fr) 2015-04-07 2016-10-13 Astrazeneca Ab Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-ones substitués utilisés comme inhibiteurs de kinase
WO2017080980A1 (fr) 2015-11-09 2017-05-18 Astrazeneca Ab Dérivés de dihydropyrrolopyrazinone utiles dans le traitement du cancer
ME03770B (fr) 2015-11-09 2021-04-20 Astrazeneca Ab Dérivés de dihydroimidazopyrazinone utiles dans le traitement du cancer
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
EP3443114A1 (fr) * 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Procédés diagnostiques et thérapeutiques relatifs au cancer
BR112019002945A2 (pt) * 2016-08-23 2019-05-21 Genentech, Inc. terapia de combinação para o tratamento de câncer pancreático
MY194462A (en) 2016-11-25 2022-11-30 Genuv Inc Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
WO2019158579A1 (fr) 2018-02-13 2019-08-22 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
US12377063B2 (en) * 2019-07-11 2025-08-05 Emory University Combination therapies for managing cancer
KR102695469B1 (ko) * 2021-07-23 2024-08-14 차의과학대학교 산학협력단 2,4-디아미노피리미딘을 포함하는 암의 예방 또는 치료용 조성물
CN118001281B (zh) * 2023-12-11 2025-10-17 中国科学院深圳先进技术研究院 一种治疗或预防甲基苯丙胺成瘾的药物及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
EP2069359B1 (fr) 2006-08-21 2014-11-12 Genentech, Inc. Composés aza-benzothiophényle et leurs procédés d'utilisation
WO2008024725A1 (fr) 2006-08-21 2008-02-28 Genentech, Inc. Composés aza-benzofuranyle et leurs procédés d'utilisation
CA2672327A1 (fr) 2006-11-30 2008-06-05 Genentech, Inc. Composes azaindolyliques et procedes d'utilisation de ceux-ci
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
WO2008157179A2 (fr) 2007-06-12 2008-12-24 Genentech, Inc. Azaindoles n-substitués et procédés d'utilisation
PE20131210A1 (es) 2007-12-19 2013-10-31 Genentech Inc Derivados de 5-anilinoimidazopiridina como inhibidores de mek
CA2704125A1 (fr) 2007-12-19 2009-07-09 Genentech, Inc. 8-anilinoimidazopyridines et leur utilisation en tant qu'agents anticancereux et/ou anti-inflammatoires
ES2387707T3 (es) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizinas y procedimientos de uso
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
WO2010003025A1 (fr) 2008-07-01 2010-01-07 Genentech, Inc. Hétérocycles bicycliques en tant qu'inhibiteurs de mek kinase
MY165154A (en) 2009-08-24 2018-02-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
NZ599939A (en) 2009-10-12 2014-02-28 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
KR101923364B1 (ko) 2010-11-23 2018-11-30 애브비 인코포레이티드 아폽토시스­유도제의 염 및 결정형
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
WO2012145503A1 (fr) 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
JP6097289B2 (ja) 2011-08-04 2017-03-15 アレイ バイオファーマ、インコーポレイテッド セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
HRP20180591T1 (hr) 2012-03-01 2018-05-18 Array Biopharma, Inc. Inhibitori kinaze serina ili treonina
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2014014308A (es) 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
JP6335169B2 (ja) 2012-08-17 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
RU2644947C2 (ru) 2012-08-27 2018-02-15 Аррэй Байофарма Инк. Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний
HRP20180670T1 (hr) 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
EP3077401B1 (fr) 2013-12-06 2018-04-18 Genentech, Inc. Inhibiteurs de sérine/thréonine kinase
MX375902B (es) 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
CA2934679C (fr) 2013-12-30 2023-02-28 Genentech, Inc. Inhibiteurs de serine/threonine kinases
KR20230006043A (ko) 2014-04-09 2023-01-10 제넨테크, 인크. 약제의 제조 방법

Also Published As

Publication number Publication date
AU2014317119B2 (en) 2019-12-05
MX2016002857A (es) 2016-06-22
ZA201600091B (en) 2017-04-26
PE20160529A1 (es) 2016-05-21
EP3041471A1 (fr) 2016-07-13
US20150111869A1 (en) 2015-04-23
PH12016500270A1 (en) 2016-05-16
EA034872B1 (ru) 2020-03-31
JP2016531139A (ja) 2016-10-06
SG11201600989VA (en) 2016-03-30
CN105517548B (zh) 2020-01-21
WO2015032840A1 (fr) 2015-03-12
JP2019031517A (ja) 2019-02-28
CA2916619A1 (fr) 2015-03-12
EA201690513A1 (ru) 2016-07-29
MX370417B (es) 2019-12-10
HK1218072A1 (zh) 2017-02-03
CL2016000042A1 (es) 2016-08-05
AU2014317119A1 (en) 2016-03-03
KR20160048807A (ko) 2016-05-04
AR097556A1 (es) 2016-03-23
TW201605477A (zh) 2016-02-16
CN105517548A (zh) 2016-04-20
IL243251B (en) 2019-02-28
US9532987B2 (en) 2017-01-03
UA120423C2 (uk) 2019-12-10

Similar Documents

Publication Publication Date Title
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
MA41013A (fr) Compositions comprenant des souches bactériennes
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA39984B1 (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
WO2019173795A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et méthodes de traitement de la maladie d'alzheimer
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
EP4585273A3 (fr) Mécanisme de résistance à des inhibiteurs de bromodomaine bet
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EP3386949A4 (fr) Inhibiteurs de glycolate oxydase et méthodes d'utilisation pour le traitement des calculs rénaux
EP3426254C0 (fr) Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées
WO2015126930A3 (fr) Pharmacothérapie à effet "booster" pour lutter contre les infections à mycobacterium
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MA41809A (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
EP3331356A4 (fr) Fragments et dérivés de la progranuline (pgrn) pour le traitement ou le soulagement des maladies lysosomales
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA42419B1 (fr) Méthode de traitement de l'encéphalopathie hépatique